Insulet sees ‘robust’ Q3
By HME News Staff
Updated 8:22 AM CST, Fri November 8, 2024
ACTON, Mass. – Insulet reported revenue of $543.9 million for the third quarter of 2023, an increase of 25.7%. Total Omnipod revenue was $533.6 million, an increase of 26.4%; of that, U.S. Omnipod revenue was $395.6 million and international Omnipod revenue was $138 million. “We continue to achieve significant milestones and robust revenue growth," said Jim Hollingshead, president and CEO. “Omnipod 5 is the first and only automated insulin delivery system in the U.S. for both Type 1 and Type 2 diabetes, following recent FDA clearance for the Type 2 label indication. Insulet leads the industry, and Omnipod 5 is revolutionizing diabetes care worldwide. I am proud of our team’s daily achievements in improving health outcomes and setting new standards in diabetes management.” Other strategic highlights: Insulet launched U.S. full market release of the Omnipod 5 App for iPhone and was named No. 1 insulin pump for new pump users in Europe. For the year ending Dec. 31, 2024, the company is raising its expected revenue growth to a range of 20% to 21%.
Comments